Dataset Information

LncRNA pulldown - The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression

ABSTRACT: lncRNA interactome study, MCF7 cells, proteomics Velos Pro

INSTRUMENT(S): LTQ

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Mammary Gland Epithelial Cell

DISEASE(S): Breast Cancer

SUBMITTER: Anton Poliakov

LAB HEAD: Felix Feng

PROVIDER: PXD002421 | Pride | 2016-10-05

REPOSITORIES: pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	F004200.dat-pride.pride.mgf.gz	Mgf
	F004200.dat-pride.pride.mztab.gz	Mztab
	F004200.dat-pride.xml.gz	Xml
	F004201.dat-pride.pride.mgf.gz	Mgf
	F004201.dat-pride.pride.mztab.gz	Mztab

Items per page:

1 - 5 of 24

Publications

The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.

Niknafs Yashar S YS Han Sumin S Ma Teng T Speers Corey C Zhang Chao C Wilder-Romans Kari K Iyer Matthew K MK Pitchiaya Sethuramasundaram S Malik Rohit R Hosono Yasuyuki Y Prensner John R JR Poliakov Anton A Singhal Udit U Xiao Lanbo L Kregel Steven S Siebenaler Ronald F RF Zhao Shuang G SG Uhl Michael M Gawronski Alexander A Hayes Daniel F DF Pierce Lori J LJ Cao Xuhong X Collins Colin C Backofen Rolf R Sahinalp Cenk S CS Rae James M JM Chinnaiyan Arul M AM Feng Felix Y FY

Nature communications 20160926

Molecular classification of cancers into subtypes has resulted in an advance in our understanding of tumour biology and treatment response across multiple tumour types. However, to date, cancer profiling has largely focused on protein-coding genes, which comprise <1% of the genome. Here we leverage a compendium of 58,648 long noncoding RNAs (lncRNAs) to subtype 947 breast cancer samples. We show that lncRNA-based profiling categorizes breast tumours by their known molecular subtypes in breast ca ...[more]

PMID: 27666543

Similar Datasets

Project description:BackgroundBreast cancer (BC) is a prevalent malignancy with complex etiology and varied clinical behavior. Long non-coding RNAs (lncRNAs) have emerged as key regulators in cancer progression, including BC. Among these, lncRNA TDRKH-AS1 has been implicated in several cancers, but its role in BC remains unclear.MethodsWe conducted a comprehensive investigation to elucidate the role of TDRKH-AS1 in BC. Clinical samples were collected from BC patients, and BC cell lines were cultured. Bioinformatics analysis using the starBase database was carried out to assess TDRKH-AS1 expression levels in BC tissue samples. Functional experiments, including knockdown, colony formation, CCK-8, Transwell, and wound-healing assays, were conducted to determine the role of TDRKH-AS1 in BC cell proliferation and invasion. Luciferase reporter and RIP assays were used to examine the interactions between TDRKH-AS1 and miR-134-5p. In addition, the downstream target gene of miR-134-5p, cAMP response element-binding protein 1 (CREB1), was identified and studied using various methods, including RT-qPCR, immunoprecipitation, and rescue experiments. In vivo experiments using mouse tumor xenograft models were conducted to examine the role of TDRKH-AS1 in BC tumorigenesis.ResultsTDRKH-AS1 was found to be significantly upregulated in BC tissues and cell lines. High TDRKH-AS1 expression correlated with advanced BC stages and worse patient outcomes. Knockdown of TDRKH-AS1 led to decreased BC cell proliferation and invasion. Mechanistically, TDRKH-AS1 acted as a sponge for miR-134-5p, thereby reducing the inhibitory effects of miR-134-5p on CREB1 expression. Overexpression of CREB1 partially rescued the effects of TDRKH-AS1 knockdown in BC cells. In vivo studies further confirmed the tumor-promoting role of TDRKH-AS1 in BC.ConclusionsOur study unveiled a novel regulatory axis involving TDRKH-AS1, miR-134-5p, and CREB1 in BC progression. TDRKH-AS1 functioned as an oncogenic lncRNA by promoting BC cell proliferation and invasion through modulation of the miR-134-5p/CREB1 axis. These findings highlighted TDRKH-AS1 as a potential diagnostic biomarker and therapeutic target for BC treatment.